As PD-1 presents the counterpart of PD-L1, it can be hypothesized, that besides the PD-L1 expression on tumor cells, the proportion of PD-1+ lymphocytes in lung cancer patients may have impact on immunotherapy action and may present a predictor for immunotherapy response. The gene discussed is PDCD1; the disease is lung carcinoma.